Gene Expression Profiling for Smoldering Myeloma Patients
Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.
Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.
Clinical pearls:
- Smoldering myeloma doesn’t act as a single disease.
- Gene expression profiling, a clinical staging system based on four genes, is used as an approach to identify high-risk progression of this disease. It is also used as technique to determine which patients would progress in one year.
- Intervention studies or treatments can be used following gene expression profiling.
Recent Videos
Related Content
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024Article
During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
